1INTRODUCTIONThe coexistence of multiple chronic conditions or comorbidity is common in older age groups including after cancer. In Australia, nearly 90 percent of cancer patients aged 45 years and over have at least one other chronic disease and approximately one‐third have three or more. A number of studies have assessed the prevalence of comorbidities in cancer patients. Some studies have examined the patterns of individual comorbidities for different types of cancer, while others have used comorbidity indices to measure the overall burden of comorbidities. However, the ability to make comparisons between studies may be limited by the differences in the demographic characteristics of study populations (e.g. age, ethnicity and socioeconomic status), types of individual comorbidities included in the analysis, the nature of the data sources (e.g. administrative hospital data vs. self‐reported) as well as the time points when comorbidities were evaluated (e.g. prior cancer diagnosis vs. ever‐experienced and after diagnosis).Comorbidity has been shown to influence treatment choices, adherence to treatment, toxicity of cancer medicines, health outcomes and use of healthcare services in cancer patients. The presence of concomitant chronic conditions may influence treatment decisions at the time of cancer diagnosis. This may be due to concerns that some patients
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera